Muscular Dystrophy

1. What is Muscular Dystrophy?
Muscular dystrophy refers to a group of inherited genetic disorders characterized by progressive weakness and degeneration of skeletal muscles.

2. What are the main types of Muscular Dystrophy?
Major types include Duchenne, Becker, limb-girdle, facioscapulohumeral, myotonic, and several other forms. Each type has different genetic causes, progression, and treatment considerations.

3. What symptoms can occur?
Symptoms may include progressive muscle weakness, difficulty running or climbing stairs, frequent falls, difficulty getting up from the floor, muscle stiffness or contractures, and loss of mobility. Some forms can also affect the heart or respiratory muscles.

4. How is Muscular Dystrophy diagnosed?
Diagnosis may involve a detailed neurological examination, blood tests such as creatine kinase, genetic testing, electromyography in selected cases, muscle imaging, and occasionally muscle biopsy. Cardiac and respiratory assessments may also be required.

5. Is there a cure for Muscular Dystrophy?
There is currently no single cure for all forms of muscular dystrophy. However, treatment has advanced considerably, and certain therapies can slow progression or address specific genetic types.

6. What treatments are available?
Management may include physiotherapy, occupational therapy, respiratory support, cardiac treatment, corticosteroids for selected conditions, disease-specific medicines, nutritional support, orthopedic treatment, and genetic therapies for certain patients.

7. Can genetic or gene-targeted therapies be used?
Some genetic therapies are available or being evaluated for particular muscular dystrophies and specific genetic mutations. Eligibility depends on the exact diagnosis, mutation, age, disease stage, and regulatory availability of the therapy.

8. What complications need monitoring?
Regular monitoring may be needed for breathing problems, cardiomyopathy and abnormal heart rhythms, joint contractures, scoliosis, swallowing difficulties, nutritional problems, and reduced mobility. Early management can help preserve function and quality of life.

9. Why consider India for Muscular Dystrophy management?
India has experienced neurologists, geneticists, pediatric specialists, rehabilitation teams, and cardiopulmonary services. Patients can access multidisciplinary evaluation, genetic testing, rehabilitation, and supportive management at comparatively competitive costs.

10. How can Medavelle help?
Medavelle can coordinate medical-record and genetic-report review, connect patients with appropriate neurology, genetics, pediatric, cardiology, respiratory, and rehabilitation specialists, assist with hospital coordination, and support international patients with non-clinical arrangements.